TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Holdings Cut by Cowen AND Company LLC

Cowen AND Company LLC reduced its stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) by 59.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,369 shares of the company’s stock after selling 30,055 shares during the period. Cowen AND Company LLC’s holdings in TriSalus Life Sciences were worth $33,000 as of its most recent SEC filing.

Separately, Clear Street LLC bought a new position in shares of TriSalus Life Sciences during the 4th quarter valued at $60,000.

TriSalus Life Sciences Price Performance

Shares of TLSIW stock opened at $1.20 on Tuesday. The stock’s 50 day simple moving average is $1.37 and its 200 day simple moving average is $1.28. TriSalus Life Sciences, Inc. has a twelve month low of $0.10 and a twelve month high of $2.23.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.